Janux Therapeutics

JANX · NASDAQ

$17.20+$0.46 (+2.75%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $16.74

JANX analyst rating

BuyConsensus of 13 analysts over the last 12 months. 77% rate it a buy.

Strong buy0
Buy10
Hold2
Underperform1
Sell0

12-month price target · 20 analysts

Average $37.12 (+115.8% upside)

Low: $14.14
Now: $17.20
High: $105.00

Upgrades and downgrades

The latest rating actions, newest first

JANX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wolfe Research	Aug 24, 2026	Upgrade	Peer Perform → Outperform	$23.00	37%
Guggenheim	Aug 7, 2026	Maintains	Buy	$58.00 → $55.00	46%
Truist Securities	Jun 25, 2026	Initiates	Buy	$80.00 → $26.00	25%
Piper Sandler	May 8, 2026	Maintains	Overweight	$30.00 → $26.00	70%
Wedbush	May 8, 2026	Maintains	Outperform	$45.00 → $36.00	39%
Guggenheim	May 8, 2026	Maintains	Buy	$68.00 → $58.00	46%
Jones Trading	Apr 28, 2026	Maintains	Buy	$50.00 → $28.00	38%
Barclays	Apr 20, 2026	Downgrade	Overweight → Underweight	$29.00 → $14.00	46%
UBS	Apr 15, 2026	Downgrade	Buy → Neutral	$57.00 → $15.00	45%
Cantor Fitzgerald	Feb 27, 2026	Maintains	Overweight	$150.00 → $100.00	49%

The case for and against

Updated Oct 14, 2026

Bull case

Janux Therapeutics is viewed positively because JANX007 is emerging as a leading PSMA TCE with potentially viable activity in mCRPC, providing proof-of-concept for the tumor-activated TRACTr platform and supporting a clear path to further optimization with better tolerability and durability. The company’s broader TRACTr, TRACIr, and ARM pipeline adds multiple shots on goal, including JANX013’s planned 2H26 clinic entry, while ~$950M+ in cash at 1Q26 and multiple pharma partnerships suggest strong financial flexibility and external validation. Investors can also point to upcoming catalysts in 1H27 and the possibility of ~ $1.8B peak revenue for JANX007 in 2035 if clinical data continue to show manageable CRS and competitive efficacy.

Bear case

Janux Therapeutics is viewed negatively because its lead program, JANX007, still faces meaningful binary clinical risk, with disappointing efficacy or poor safety potentially undermining the investment case despite hopes it could compete with Pluvicto in mCRPC, a market annualizing roughly $2B. The stock also trades at negative EV after the 12/2025 update, signaling that investor confidence has already been damaged and that the shares remain vulnerable to further disappointment. Beyond clinical execution, the company must still overcome delays in R&D, regulatory and commercial development, competitive pressure in mCRPC, and the risk of not raising sufficient capital to fund research.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.